论文部分内容阅读
目的研究雌激素受体(ER)与尿激酶型纤溶酶原激活物(urokinase-type plasminogen activator,uPA)在乳腺癌组织中的表达及其临床意义。方法免疫组织化学染色采用PV-6000二步法,对40例乳腺癌蜡块中ER、uPA表达进行研究。结果乳腺腺瘤、腺病和乳腺癌中ER阳性率分别为85.0%、82.5%和60.6%,三者差异有统计学意义(P<0.05);ER表达阳性患者淋巴结转移率(33.33%)低于ER表达阴性者(81.25%),差异有统计学意义(P<0.01)。uPA在乳腺纤维腺瘤、腺病均呈阴性表达,在乳腺癌中的阳性率为60.00%,三者差异有统计学意义(P<0.05);uPA表达阳性患者淋巴结转移率(88.5%)显著高于阴性者(50.0%),两者的表达差异有统计学意义(P<0.05)。结论 uPA的高表达和ER的缺失表达与乳腺癌的浸润转移密切相关,检测ER和uPA对临床选择治疗方法有指导意义。
Objective To study the expression of estrogen receptor (ER) and urokinase-type plasminogen activator (uPA) in breast cancer and its clinical significance. Methods Immunohistochemical staining PV-6000 two-step method was used to study the expression of ER and uPA in 40 cases of breast cancer. Results The positive rate of ER in breast adenoma, adenosis and breast cancer was 85.0%, 82.5% and 60.6%, respectively (P <0.05). The rate of lymph node metastasis (33.33%) in patients with ER positive expression was lower In ER-negative patients (81.25%), the difference was statistically significant (P <0.01). The positive rate of uPA in breast fibroadenoma and adenosis was 60.00%, the difference was statistically significant (P <0.05). The rate of lymph node metastasis (88.5%) in uPA positive patients was significant Higher than negative (50.0%), the difference was statistically significant (P <0.05). Conclusion The high expression of uPA and the deletion of ER are closely related to the infiltration and metastasis of breast cancer. The detection of ER and uPA may be instructive for the clinical choice of treatment.